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Abstract
Long-term administration of nitrogen-containing bisphosphonates can induce detrimental side effects
such as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in human. Although inflammation is
known to be associated with BRONJ development, the detailed underlying mechanism remains unknown.
Here, we report that the pro-inflammatory cytokine IL-36α is, in part, responsible for the BRONJ
development. We found a notably higher level of IL-36α and lower level of collagen in the BRONJ lesions
in mice. We also found that IL-36α remarkably suppressed TGF-β-mediated expression of Collα1 and αSma via the activation of Erk signaling pathway in mouse gingival mesenchymal stem cells. When IL-36
signaling was abrogated in vivo, development of BRONJ lesions was ameliorated in mice. Taken together,
we showed the pathologic role of IL-36α in BRONJ development by inhibiting collagen expression and
demonstrated that IL-36α could be a potential marker and a therapeutic target for the prevention and
treatment of BRONJ.
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Abstract
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Long-term administration of nitrogen-containing bisphosphonates can induce detrimental side
effects such as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in human. Although
inflammation is known to be associated with BRONJ development, the detailed underlying
mechanism remains unknown. Here, we report that the pro-inflammatory cytokine IL-36α is, in
part, responsible for the BRONJ development. We found a notably higher level of IL-36α and
lower level of collagen in the BRONJ lesions in mice. We also found that IL-36α remarkably
suppressed TGF-β-mediated expression of Collα1 and α-Sma via the activation of Erk signaling
pathway in mouse gingival mesenchymal stem cells. When IL-36 signaling was abrogated in vivo,
development of BRONJ lesions was ameliorated in mice. Taken together, we showed the
pathologic role of IL-36α in BRONJ development by inhibiting collagen expression and
demonstrated that IL-36α could be a potential marker and a therapeutic target for the prevention
and treatment of BRONJ.
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Introduction
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Nitrogen-containing bisphosphonates (N-BPs) are anti-resorptive drugs commonly
prescribed to treat bone disorders such as osteoporosis(1) or bone metastasis in cancer
patients.(2) Long-term users of these drugs are at a higher risk of developing
bisphosphonate-related osteonecrosis of the jaw (BRONJ), a rare but detrimental side effect
that specifically occurs in the oral cavity. A recent position paper reported by the American
Association of Oral and Maxillofacial Surgeons (AAOMS) redefined the definition of
BRONJ to mediation-related ONJ (MRONJ) to be more inclusive of other medications that
are associated with ONJ, such as denosumab or bevacizumab.(3) MRONJ is clinically
defined as exposed necrotic bone with incomplete oral mucosal closure for at least 8 weeks
without history of radiation exposure to the head and neck. Although the first report of ONJ
induced by N-BPs was published in 2003,(4) the exact pathophysiology of ONJ development
is still largely unknown.
Currently, several risk factors are known to be associated with ONJ development. Among
them, dental-related trauma such as a tooth extraction is one of the major risk factors
significantly associated with ONJ development in N-BP or Dmab users.(5) In clinics, a tooth
extraction procedure is usually performed because of underlying pathological conditions
such as severe periodontitis or periapical endodontic lesions, which cause destruction to the
surrounding environment should the affected tooth remain unextracted. Indeed, preexisting
pathological inflammatory conditions such as periodontal or periapical diseases are also
known to be risk factors for ONJ development.(5,6) As such, these clinical observations
suggest that, in addition to tooth extraction, certain inflammatory cues may be associated
with ONJ development.

Author Manuscript

IL-36 family genes are relatively new members of the interleukin-1 (IL-1) family that were
identified based on their sequence similarity to IL-1α and IL-1β.(7) Originally named as
IL-1F6, IL-1F8, and IL-1F9, their designations were changed to IL-36α, IL-36β, and
IL-36γ, respectively, because of their similarity in functions.(8) All three IL-36 members
elicit signaling through IL-1 receptor-related protein 2 (IL-1Rrp2) and IL-1 receptor
accessory protein (IL-1RAcP)—two subunits that make up the IL-36 receptor—and activate
pathways such as NF-κB, p38, or Erk.(9,10) Increasing lines of evidence support a notion that
IL-36 is implicated in inflammation-related human diseases such as psoriasis, alopecia, brain
micromotion, obesity, joint disease, and allergen-induced lung inflammation.(11) However,
whether IL-36 has any pathologic roles in ONJ development is yet to be determined.

Author Manuscript

Previously, we showed that both N-BP and Dmab induced ONJ-like lesions in mice.(12)
Although the mechanisms of actions for N-BP and Dmab are clearly different,(13) our study
and clinical findings suggest that both drugs can induce ONJ development.(3,12) Therefore,
in this study, we specifically focused on examining the underlying mechanisms of ONJ
development by bisphosphonates. To better understand the mechanisms by which BRONJ
develops at the molecular level, we performed a microarray analysis using osteomucosal
tissues obtained from tooth-extracted sites in BP- or vehicle (Veh)-treated mice and explored
differentially regulated genes in vivo. Here, we identified pro-inflammatory cytokine IL-36α
as one of the genes highly upregulated in ONJ lesions and demonstrated that IL-36α plays
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an etiological role in BRONJ development. We also provide mechanistic evidence that there
is a cross-talk between the IL-36 and TGF-β signaling pathways, leading to inhibition of
collagen expression. Finally, we show that abrogation of the IL-36α signaling pathway
significantly ameliorates BRONJ development in mice.

Materials and Methods
Reagents and antibodies

Author Manuscript

The following reagents were used: Erk inhibitor, U0126 (Sigma-Aldrich, St. Louis, MO,
USA); ZOL (LKT Laboratories, St. Paul, MN, USA), and Zometa (Novartis Oncology, East
Hanover, NJ, USA). Recombinant IL-36α (7059-ML), IL-36β (7060-ML), IL-36γ (6996ML), and TGF-β (7666-MB) were obtained from R&D Systems (Minneapolis, MN, USA).
The following antibodies were used: mouse anti-IL-36α from R&D Systems; mouse anti-αSma and mouse anti-α-tubulin from Sigma-Aldrich; rabbit anti-p-Smad2, mouse antiSmad2, rabbit anti-p-IκBα, rabbit anti-IκBα, rabbit anti-p-p38, rabbit anti-p38, rabbit antip-p65, rabbit anti-p-Erk 1/2, and rabbit anti-Erk 1/2 from Cell Signaling Technology
(Danvers, MA, USA); mouse anti-p65 from Millipore (Chicago, IL, USA); and rabbit antiCol1a1, rabbit anti-lamin B1, and mouse anti-Gapdh from Santa Cruz Biotechnology
(Dallas, TX, USA). IL-1Rrp2 neutralizing antibody used in the mice study was obtained
from Amgen (Thousand Oaks, CA, USA).
Cells and cell culture

Author Manuscript

Primary gingival mesenchymal stem cells (GMSCs) were isolated from the mouse’s palatal
tissues as described previously.(14) Briefly, palatal tissues from C57BL/6 mice were excised
and minced into small pieces, which were then subjected to collagen digestion in 37°C for 2
hours with constant agitation. Digested tissues were then collected, washed, and plated onto
the culture dish containing α-MEM (Life Technologies, Carlsbad, CA, USA), 20% FBS
(Life Technologies), glutamine (200 mM; Life Technologies), and 2-mercaptoethanol (55
mM; Sigma-Aldrich). From this primary culture, multi-colonies were obtained and
maintained. GMSCs that are under 5 passages were used. To knockdown expression of
IL-1Rrp2, we transfected IL-1Rrp2 siRNA (Santa Cruz) using Lipofectamine RNAimax
(Life Technologies) for 12 hours. IL-36α was then added for additional 2 days, and the cells
were harvested for qRT-PCR analysis. All experiments using mice in this study were
performed according to the approved institutional guidelines from the Chancellor’s Animal
Research Committee (ARC # 2011-062).
Animals

Author Manuscript

Eight-week-old female C57BL/6 mice were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA) and IL-1Rrp2 KO mice were obtained from Taconic Bioscience
(Hudson, NY, USA). All mice were kept in a pathogen-free vivarium in the UCLA Division
of Laboratory Animal Medicine (DLAM) according to the approved institutional guidelines
from the Chancellor’s Animal Research Committee (#2011-062). The mouse model for
BRONJ used in this study is previously described.(12) Briefly, ZOL (Zometa, 125 µg/kg;
Novartis Oncology) or vehicle (Veh) solution (0.9% NaCl saline) was intravenously
administered biweekly throughout the experiment (n = 5–10 per group). One week after
J Bone Miner Res. Author manuscript; available in PMC 2018 February 01.
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ZOL administration, maxillary first molar was extracted and allowed to heal. After 2 weeks,
maxillae were harvested, and osteomucosal tissues at the tooth-extracted sites were excised
and subjected to further analysis for microarray. For BRONJ-rescue experiments, antiIL-1Rrp2 neutralizing antibody was administered 1 week before ZOL administration. One
week after ZOL administration, maxillary first molar was extracted, mice were allowed to
heal for 3 weeks, and the maxillae were harvested for further analysis.
cDNA microarray

Author Manuscript

Gene expression profiling was performed using the Affymetrix GeneChip Mouse 430 2.0
Array (Affymetrix, Santa Clara, CA, USA). Total RNA was extracted from osteomucosal
samples of BRONJ-like lesions using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instruction. RNA integrity was evaluated using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA), and purity/concentration
was determined using a NanoDrop 8000 (NanoDrop Products, Wilmington, DE, USA).
Microarray experiments were performed at UCLA CMC. Microarray targets were prepared
using NuGEN WT-Ovation Formalin-Fixed Paraffin-Embedded RNA Amplification System
and FL-Ovation cDNA Biotin Module V2 (NuGEN Technologies, San Carlos, CA, USA)
and then hybridized to the array, all according to the manufacturer’s instructions. The arrays
were washed and stained with streptavidin phycoerythrin in Affymetrix Fluidics Station 450
using the Affymetrix GeneChip protocol and then scanned using an Affymetrix GeneChip
Scanner 3000. The acquisition and initial quantification of array images were conducted
using the AGCC software (Affymetrix). The subsequent data analyses were performed using
Partek Genomics Suite Version 6.4 (Partek, St. Louis, MO, USA). Differentially expressed
genes were selected at ≥2-fold and p< 0.005.

Author Manuscript

Micro-computed tomography (µCT) scan and three-dimensional volumetric analysis
The harvested maxillae were fixed with 4% paraformaldehyde in PBS, pH 7.4, at 4°C
overnight and stored in 70% ethanol solution. The fixed maxillae were subjected to µCT
scanning (Scanco µCT 40, Scanco Medical, Brüttisellen, Switzerland) using a voxel size of
20 µm3 and a 0.5 mm aluminum filter. Two-dimensional slices from each maxilla were
combined using µCT v6.1 software (Scanco Medical) to form a three-dimensional
reconstruction. Reconstructions were further analyzed so that the viewing angles could
provide an accurate representation of bone resorption after 3 weeks of healing. The scanning
and analyses of data abide by the published guidelines for assessing bone microstructure in
rodents.(15)
Histomorphometric analysis

Author Manuscript

After µCT scanning, these tissues were decalcified with 5% EDTA and 4% sucrose in PBS
(pH 7.4). Decalcification continued for 2 to 3 weeks at 4°C. The decalcification solution was
changed daily. Tissue samples were sent to the UCLA Translational Procurement Core
Laboratory (TPCL) and processed for paraffin embedding.
Amounts of empty lacunae and necrotic bone percentages were evaluated as described
previously.(12) Briefly, four sections (#1, #6, #11, and #16) per sample in 5 µm thickness
were stained with H&E. For each section that contains an area of interest covering first
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molar extracted sites horizontally from the buccal plates toward the palatal suture (~1.4 mm)
and vertically from the tip of the extracted site to the bottom of the palatal bone (~0.8mm),
the digital images of each section were obtained using the microscope (Olympus, DP72) at
100×. The percentage of necrotic bone was defined as an area that contains five or more
empty lacunae per 1 mm2 divided by total bone areas. The number of empty lacunae was
also evaluated per total bone area (#/mm2). The total bone surface area was measured using
ImageJ software.
Immunohistochemical (IHC) staining

Author Manuscript

IL-36 expression was determined as described previously.(16) Briefly, slides were
deparaffinized at 60°C in oven for 30 minutes followed by rehydration in xylene and
ethanol. The slides were then unmasked in citrate buffer (6 mM citric acid/34 mM sodium
citrate/pH.6.0) above 95°C for 25 minutes, and the endogenous peroxidase were blocked
with 3% hydrogen peroxide (H2O2). The slides were incubated with 10% blocking buffer for
30 minutes, anti-IL-36 antibody or anti-mouse IgG (Vector Laboratories, Burlingame, CA,
USA) antibodies (1:100) in 3% blocking buffer for 90 minutes, secondary antibody (1:200)
in 3% blocking buffer for 60 minutes, and HRP-Avidin (1:1000) in PBST for 30 minutes.
The slides were developed using DAB substrate kit (Vector Laboratories).
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)

Author Manuscript

Total RNA was isolated from the cultured cells using RNeasy Plus Mini Kit (Qiagen). DNAfree total RNA (5 µg) was dissolved in 15 µL DEPC-H2O, and the RT reaction was
performed in first-strand buffer (Invitrogen) containing 300U Superscript II (Invitrogen), 10
mM DTT, 0.5 µg random hexamer (Promega Corporation, Madison, WI, USA), and 125 µM
dNTPs. The annealing reaction was carried out for 5 minutes at 65°C, and cDNA synthesis
was performed for 2 hours at 37°C, followed by incubation for 15 minutes at 70°C to stop
the enzyme reaction. The RT product was diluted with 70 µl H2O. The primers used for PCR
amplification are listed in Supplemental Table S1.
Nuclear and cytoplasmic proteins fractionation
Cells were pretreated with IL-36 α for 6 hours and then treated with TGF-β1 for 2 hours.
After cells were harvested, nuclear and cytoplasmic proteins were isolated using the NEPER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce, Rockford, IL, USA)
following the manufacturer’s instructions.
Western blotting

Author Manuscript

Cells were washed twice with PBS before treatment with ice-cold lysis buffer (20 mM TrisHCl, pH 7.4, 150 mM NaCl, 5 mM EDTA and 1% Triton X-100). And then, the cells were
scraped and incubated on ice for 10 minutes. Cell debris was separated by centrifugation at
20,000g at 4°C for 20 minutes and the supernatant was collected for Western blot analysis
after 8% or 10% SDS-PAGE. After electrophoresis, proteins were transferred to
immobilized membrane (Millipore), which was subsequently blocked with 5% non-fat milk
for 1 hour at room temperature. Then, membrane was incubated with primary antibodies,
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and probed with the respective secondary antibodies conjugated with HRP. The signals were
obtained using ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA).
ELISA
Sera collected from each mouse was stored in −20°C and thawed once. The presence of
TRAP-5b was detected by sandwich ELISA using the MouseTRAP Kit (Immunodiagnostic
Systems, Fountain Hills, AZ, USA). Systemic levels of IL-36α were detected by sandwich
ELISA established in our laboratory using IL-36α and biotinylated IL-36α antibodies
(AF2297 and BAF2297; R&D Systems). Soluble collagens were detected according to
manufacturer’s protocol using the Sircol assay kit (QZBCOL1-1; Cedarlane Laboratories,
Burlington, NC, USA).
Chromatin immunoprecipitation (ChIP) assay

Author Manuscript

Cells were fixed at room temperature for 10 minutes in the culture medium containing 1%
formaldehyde, and ChIP assay was performed using the MAGnify ChIP System (Invitrogen)
according to the manufacturer’s instructions. Col1a1 and α-Sma antibodies were coupled to
Dynabeads, and the antibody-coupled Dynabeads were incubated with the sheared
chromatin. Chromatin-antibody-Dynabeads complexes were then washed with washing
buffers, and the cross-links were reversed in the presence of Proteinase K. The uncrosslinked DNA was purified using the DNA Purification Magnetic Beads. The purified DNA
fragments were amplified using primer sets. These primers are listed in Supplemental Table
S2.
Statistical analysis

Author Manuscript

The outcome measurements were expressed as means ± standard deviation. To compare the
outcome mean measurements among the different groups, we used one-way ANOVA with
Tukey’s post hoc test. For comparison between two groups, Student’s t test was used. All
statistical tests were performed using the SPSS 23 software (IBM, Somers, NY, USA). Any
p values <0.05 are considered significant.

Results
Microarray gene profiling identifies overexpressed IL-36 family members in ONJ-like
lesions in mice

Author Manuscript

Previously, we demonstrated that BP administration followed by tooth extraction induced
ONJ-like lesions in mice.(12) To further gain molecular insights, we utilized a highthroughput micro-array screening system and compared differentially expressing genes in
tissues obtained from ONJ lesions (Fig. 1A). Consistent with our previous report,(12) toothextracted sockets were filled in with new bone in the Veh-treated groups but remained
unfilled in ZOL-treated groups (Fig. 1B). These unhealed osteomucosal tissues at the toothextracted sites were subjected to microarray profiling, and differentially expressed genes that
were either upregulated or downregulated more than fivefold were obtained (Fig. 1C,
Supplemental Table S3). When these genes were further analyzed using the ingenuity
pathway analysis (IPA), we identified “biosynthesis of steroids” as the most significantly
associated functional pathway (Fig. 1D). The primary target of N-BPs is farnesyl
J Bone Miner Res. Author manuscript; available in PMC 2018 February 01.
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diphosphate synthase (FDPS), the branch-point enzyme in the mevalonate pathway partly
responsible for steroid synthesis.(17) Interestingly, genes involved in this pathway such as
FDPS were all upregulated (Fig. 1E), presumably because of compensatory mechanisms of
directly blocking the mevalonate pathway by N-BP,(18) demonstrating the validity of our
BRONJ mouse model. The second functional pathway that is associated with ONJ lesions
was “role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis” (Fig. 1D).
Among these genes, expression of IL-1 family cytokines IL-1F4 (IL-18), IL-1F5 (IL-36RN),
IL-1F6 (IL-36α), and IL-1F8 (IL-36β) were highly upregulated (Fig. 1F). Because IL-36
family members were all significantly upregulated, we further analyzed the role of these
genes and their possible involvement in ONJ development.
IL-36 is overexpressed in BRONJ-like lesions in mice

Author Manuscript

To confirm the microarray results, we first validated expression of IL-36 in BRONJ lesions.
Consistent with the microarray data, we found increased expression of IL-18, IL-36α,
IL-36β, and FDPS, but not IL-36γ, in a BRONJ-specific manner (Fig. 1G, K).
Immunohistochemical analysis against IL-36α and IL-18 showed high levels of both IL-36α
and IL-18 at the leading edge of epithelia near the wounded site in BRONJ but not in Vehtreated mice (Fig. 1L). The serum level of IL-36α, but not IL-18, in ZOL-treated mice was
also significantly elevated when compared with the Veh-treated mice (Fig. 1M, N).
Collectively, these data suggest that IL-36α is upregulated both locally and systemically in
mice with BRONJ-like lesions.
IL-36 inhibits TGF-β-mediated collagen expression in GMSCs

Author Manuscript
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One of the hallmarks in the BRONJ lesions in patients is denuded bone with a lack of
covering collagen-enriched connective tissue layers.(3) In gingival connective tissue, type I
collagen (Col1a1) is the major constituent.(19) Further analysis from the microarray data
revealed that many genes associated with connective tissues (ie, collagenous and noncollagenous proteins) including Col1a1 were significantly downregulated in BRONJ-like
lesions (Fig. 2A). Collagen is an essential protein in proper wound healing, and
dysregulation of collagen deposition by fibroblasts leads to impaired wound healing.(20)
Thus, we examined whether IL-36 plays any role in suppressing collagen expression. When
we treated gingival mesenchymal stem cells (GMSCs) with recombinant IL-36α, IL-36β, or
IL-36γ, there was significant induction of IL-6 expression (Fig. 2B), a known target of
IL-36.(21) When we examined expression of Col1a1, Col1a2, and Col3a1, they were all
suppressed at the mRNA level (Fig. 2C). Knockdown of IL-1Rrp2 rescued suppressed
collagen expression of Col1a1 and Col1a2 but not Col3a1, suggesting that IL-36 may
mediate the expression of Col3a1 differently from that of Col1a1 and Col1a2 (Fig. 2D, E).
Interestingly, IL-36 treatment did not show any drastic effects at the protein expression level,
presumably because of low basal collagen expression (Fig. 2F, left two panels). Because
TGF-β is known to play an important role in wound healing by controlling collagen
synthesis,(22) we tested whether IL-36α suppresses TGF-β-mediated collagen expression.
Indeed, TGF-β significantly induced protein levels of Col1a1 as well as α-Sma, which is
required for wound contraction,(23) but such induction was suppressed by IL-36α treatment
(Fig. 2F, right two panels). Secreted collagen was also suppressed by IL-36α treatment (Fig.
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2G). Similar results were noted at the mRNA level, suggesting that IL-36α suppresses TGFβ-mediated expression of Col1a1, Col1a2, and α-Sma at the transcriptional level (Fig. 2H).
IL-36α inhibits TGF-β-mediated nuclear translocation of the Smad complex by activating
the Erk signaling pathway

Author Manuscript

To further gain molecular insights as to how IL-36α suppresses TGF-β-mediated collagen
expression, we examined whether Smad signaling is altered by IL-36α. When
phosphorylated Smad2 (p-Smad2) was screened in the whole cell lysate of GMSCs treated
with TGF-β and different doses of IL-36α, we found no differences in p-Smad2 level (Fig.
3A). However, there was a significant reduction of p-Smad2 in the nuclear fractions in a
dose-dependent manner (Fig. 3B), whereas p-Smad2 level in the cytoplasmic fractions was
not affected (Fig. 3C), indicating that IL-36α inhibited TGF-β-activated nuclear
translocation of the Smad complex. Consistent with this finding, the occupancy of Smad2 in
the Col1a1 and α-Sma promoters by TGF-β was significantly reduced by IL-36α (Fig. 3D,
E).

Author Manuscript
Author Manuscript

IL-36 is known to activate several intracellular signaling pathways including NF-κB, p38,
and Erk.(24) In particular, activation of the NF-κB signaling pathway by IL-36α has been
previously shown.(10) To investigate which intra-signaling pathway is responsible for
IL-36α-mediated suppression of collagen expression by TGF-β in GMSCs, we treated
GMSCs with different doses of IL-36α and screened for activation of these pathways. IL-36
activated both NF-κB and MAPK signaling pathways as determined by induced
phosphorylation of p65 and Erk1/2 (Fig. 3F). Interestingly, there was no phosphorylation of
IκBα, a required step for its own degradation, which in turns allows for nuclear
translocation of NF-κB complex,(25) suggesting that effects of IL-36α on the NF-κB
signaling pathway may be dispensable. Indeed, a recent study demonstrated that IL-36α
does not have any effects on osteoclast formation in which the NF-κB signaling pathway is
known to play a critical functional role.(26) On the other hand, there was a notable increase
in p-Erk 1/2 (Fig. 3F). When the Erk signaling pathway was inhibited by the Erk-specific
inhibitor, U0126, IL-36α-mediated suppression of Col1a1 and α-Sma expression was
rescued (Fig. 3G, H). Furthermore, U0126 rescued IL-36α-mediated inhibition of p-Smad2
nuclear translocation in TGF-β-treated GMSCs (Fig. 3I, J), indicating that the activation of
Erk1/2 has a predominant and functional role in IL-36α-treated GMSCs. Our study is
consistent with the previous finding that activation of Erk1/2 signaling pathway disrupts
TGF-β1-stimulated Smad2/3 nuclear translocation.(27) When GMSCs obtained from Rrp2−/−
mice were treated with IL-36α, suppression of TGF-β-mediated p-Smad2 was also
abolished in nuclear but not cytoplasmic fractions (Fig. 3K–N), further confirming that
activation of the IL-36 signaling pathway via the IL-36 receptor is required for inhibition of
TGF-β-activated nuclear translocation of the Smad complex. These data indicate that
IL-36α inhibits TGF-β-activated nuclear translocation of the Smad complex by activating
the Erk signaling pathway.
The IL-1Rrp2 neutralizing antibody rescues BRONJ-like lesions in mice
We next examined whether blocking the IL-36 signaling pathway by targeting the IL-36
receptor, IL-1Rrp2, would rescue BRONJ lesions in mice. When IL-1Rrp2 was knocked
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down in GMSCs, collagen expression suppressed by IL-36α was rescued in vitro (Fig. 2D,
E). To block the IL-36 signaling pathway in vivo, we used an anti-IL-1Rrp2 neutralizing
antibody (Fig. 4A). Administration of the anti-IL-1Rrp2 neutralizing antibody itself did not
alter any effects of bisphosphonates in vivo as demonstrated by circulating tartrate-resistant
acid phosphatase (TRAP) 5b (Fig. 4B), an indicator of activated osteoclast number.(28)
When mice were harvested, we found that 20% of the mice treated with ZOL alone had
exposed bone, results of which is consistent with previous findings,(12,29) indicating
breached oral mucosal tissues and unfilled tooth-extracted sockets, respectively (Fig. 4C, D,
third row). In contrast, no exposed bone was found in any of the other test groups, including
ZOL in combination with anti-IL-1Rrp2 neutralizing antibody (Fig. 4C, D). Histological
examination revealed an absence of connective tissues on the exposed bone area in the ZOLtreated group, whereas complete oral mucosal closures were noted in the other groups (Fig.
4E). Further analysis showed that empty lacunae and necrotic bone was significantly rescued
in the presence of anti-IL-1Rrp2 neutralizing antibody (Fig. 4F, G), indicating that blocking
the IL-36 signaling pathway ameliorated BRONJ lesions in mice.

Discussion

Author Manuscript

In this study, we showed that the pro-inflammatory cytokine IL-36 is a putative molecular
determinant in BRONJ development by providing compelling evidence at the molecular,
cellular, and organismal levels. We also demonstrated a novel cross-talk between IL-36 and
TGF-β; IL-36 activates the Erk signaling pathway, which inhibits TGF-β-activated nuclear
translocation of the Smad complex (Figs. 2, 3, and 5). To the best of our knowledge, our
study is the first report demonstrating the involvement of IL-36 in BRONJ development,
adding another pathologic role of IL-36 to the growing list of the IL-36-mediated human
diseases and shedding new insights as to how ONJ develops, at least by N-BPs.
IL-36 is implicated in inflammation-related human diseases by targeting immune cells.(30)
Interestingly, a recent study suggested that IL-36 can also assert its effects on non-immune
cells that express IL-1Rrp2; IL-36α secreted from CD138-postive plasma cells in the
psoriatic and rheumatoid arthritis synovium induced expression of IL-6 and IL-8 in synovial
fibroblasts.(31) Similarly, our study demonstrated that GMSCs express a high level of
IL-1Rrp2 and that IL-36α significantly inhibits TGF-β-mediated expression of Col1a1 and
α-Sma (Figs. 2 and 3), suggesting the diverse involvement of IL-36 in pathologic lesions.
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Although our study demonstrated the upregulation of IL-36 in ZOL-treated mice in an ONJspecific manner and the suppression of collagen expression by IL-36, the source of IL-36 is
yet to be determined. Studies suggest that IL-36 is predominantly expressed in keratinocytes
and is known to play a role in psoriasis via its interplay with psoriasis-associated cytokines
such TNF-α, IL-6, and IL-17.(11,32) Indeed, our IHC staining showed that IL-36 is heavily
expressed at the migrating tongue of the epithelial cells that are specific to BRONJ lesions,
suggesting IL-36 is primarily secreted by epithelial cells when the healing process (eg,
wound closure) is incomplete by BPs, leading to BRONJ lesions.
On the contrary, IL-36 is also significantly produced by monocyte-lineages such as dendritic
cells and macrophages.(7,33) Because osteoclasts are derived from monocyte/macrophage
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lineages and are the first cells to encounter BPs when BPs are leached out from bone during
resorption, it is tempting to speculate that BPs taken up by osteoclasts may cause significant
release of IL-36, interfering with local collagen formation. Further studies are required to
elucidate the primary sources of IL-36 that play an etiologic role in BRONJ.
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Several lines of evidence from previous studies support a notion that IL-36 may play
additional etiological roles in ONJ development. First, IL-36 in human keratinocytes can be
induced by IL-17,(32) an important cytokine known to be associated with BRONJ.(34)
Second, IL-36 is shown to be present in the gingival crevicular fluid in periodontal diseases,
one of the known risk factors for ONJ development.(3,35) Third, induction of IL-36 is also
observed in response to microbial or viral exposures,(36,37) and externalization of
cytoplasmic IL-36 occurs when challenged by bacterial lipopolysaccharide.(38) Because
bacterial infection is commonly found in ONJ lesions, in part because of their preferential
adhesion to the exposed bone hydroxyapatite,(39,40) it is possible that the latter notion may
result in amplification of IL-36 production at the local level and play a pathological role in
ONJ lesions.
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The current study is in line with our previous finding in which we demonstrated that
deregulation in woven bone formation within the tooth-extracted sockets are associated with
ONJ development by BPs.(12) One of the early steps in woven bone formation is collagen
secretion to the extracellular matrix onto which osteoblasts start forming mineralization.(41)
The TGF-β1 signaling pathway is significantly upregulated during the initial stages and
mediates the wound healing.(42,43) Reduced TGF-β1 expression was observed in impaired
wound healing and chronic ulcerations.(44,45) It is noteworthy that the TGF-β1 signaling
pathway is significantly suppressed in BRONJ lesions at the clinical level.(46) Therefore, a
possibility exists whereby inhibition of the initial osteomucosal wound healing process in
the oral cavity by suppressing the TGF-β1 signaling pathway and woven bone formation
may contribute to ONJ development.
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Although our study demonstrated the involvement of IL-36 on ONJ development by N-BPs,
the limitation of the current study is that it is not known whether IL-36 also etiologically
causes ONJ development by Dmab. Our preliminary study showed that IL-36 expression is
notably elevated in the DRONJ lesions in mice (unpublished data). Because Dmab
completely abolishes osteoclast formation in vivo, the effects of IL-36 in DRONJ
development may be indirectly associated with factors other than dysfunctional osteoclasts
per se such as inflammation associated with unhealing tooth-extracted site. Such speculation
is particularly plausible when both BRONJ and DRONJ lesions commonly exhibit the
exposed necrotic bone without any overlaying connective tissues. The functional role of
IL-36 in DRONJ development needs further clarification.
In conclusion, we have shown that IL-36 plays an etiological role in BRONJ development.
Because there are no currently available therapeutic modalities for BRONJ development,
utilizing IL-36 as a therapeutic target to ameliorate BRONJ lesions in patients warrants
further investigation. Similarly, further study on the role of IL-36 in DRONJ development
would provide additional clues whether inhibiting IL-36 signaling pathway may be
therapeutically beneficial to managing MRONJ in general.
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Microarray gene profiling identifies overexpressed IL-36 family members in ONJ-like
lesions in mice. (A) A graphic representation of timeline used in this study. (B) Clinical
illustration of the osteomucosal tissues before and after removal at the tooth-extracted areas
photographed 2 weeks after tooth extraction. (C) A graphic representation of the microarray
profiling that are differentially expressed more than fivefold were represented (n = 3 per
group). (D) The ingenuity pathway analysis (IPA) of functional pathways that are associated
with ONJ lesions. (E) Lists of genes involved in biosynthesis of steroids. (F) List of genes
involved in role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis. The
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unhealed osteomucosal tissues at the tooth-extracted sites were harvested and subjected
mRNA isolation, cDNA synthesis, and qRT-PCR for (G) IL-18, (H) IL-36α, (I) IL-36β, (J)
IL-36γ, and (K) FDPS. The results are from two independent non-BRONJ and BRONJ
lesions. (L) Staining for H&E and IHC staining for IL-36α at the tooth-extracted sites in
vehicle (Veh)- or Zometa (ZOL)-treated mice. Scale bar = 100 µm. ELISA for (M) IL-18
and (N) IL-36α from the serum obtained from Veh- or ZOL-treated mice 2 weeks after tooth
extraction. *p<0.05; **p<0.01; ***p<0.001. Results represent the means ± SD performed in
triplicate unless otherwise indicated.
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Fig. 2.
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IL-36α inhibits expression of collagen and α-Sma in GMSCs. (A) List of genes associated
with connective tissues (eg, collagenous and non-collagenous proteins) from the microarray
data. (B) qRT-PCR of Il-6 in gingival mesenchymal stem cells (GMSCs) treated with
recombinant IL-36α, IL-36β, and IL-36γ for 4 days. (C) qRT-PCR of Col1a1, Col1a2, and
Col3a1 in GMSCs treated with recombinant IL-36α, IL-36β, and IL-36γ for 4 days. (D)
Western blotting of IL-1Rrp2 after knocking down with control siRNA (CTLsi) or IL-1Rrp2
siRNA (IL-1Rrp2si) in GMSCs. (E) qRT-PCR of Col1a1, Col1a2, and Col3a1 in GMSCs
with IL-1Rrp2 knockdown and IL-36a treatment. (F) Western blotting of Col1a1 and α-Sma
in GMSCs treated with IL-36α and TGF-β1 for 2 days. (G) ELISA for collagen type I from
supernatants obtained from GMSCs treated with IL-36α and TGF-β1. (H) qRT-PCR of
Col1a1, Col1a2, and α-Sma in GMSCs treated with recombinant IL-36α and TGF-β1 for 2
days. *p<0.05; **p<0.01; ***p<0.001. Results represent the means ± SD performed in
triplicate.
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Fig. 3.
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IL-36α inhibits nuclear translocation of activated Smad complex upon TGF-β1 treatment by
activating the Erk signaling pathway. (A, C) Western blotting for p-Smad2 and Smad2 from
the whole cell lysates, the nuclear extracts, and the cytoplasmic extracts in GMSCs treated
with IL-36α for 6 hours and TGF-β1 for 2 hours. (D, E) Chromatin immunoprecipitation
(ChIP) assay using IgG or Smad2 antibody followed by qRT-PCR using primers specific to
the promoter regions of Col1a1 and α-Sma. The values were normalized to the internal
control. (F) Western blotting for indicated antibodies in GMSCs treated with IL-36α or
TNF-α for 6 hours. (G, H) qRT-PCR analysis for Col1a1 and α-Sma in GMSCs treated with
U0126 (10 µM) and IL-36α (10 ng/mL) for 6 hours before adding TGF-β1 (10 ng/mL).
Cells were harvested after 2 days. (I, J) Western blotting against p-Smad2 and Smad2 from
the nuclear and cytoplasmic extracts. (K) PCR for genomic IL-1Rrp2 in GMSCs obtained
from IL-1Rrp2+/+ or IL-1Rrp2−/− mice. (L, M) Western blotting for p-Smad2 from the
nuclear and cytoplasmic extracts in IL-1Rrp2+/+ or IL-1Rrp2−/− GMSCs treated with IL-36α
for 6 hours followed by TGF-β1 for 2 hours. (N) Quantification of the Western blotting (L)
of p-Smad2 normalized to the Lamin B1 using ImageJ. *p<0.05; **p<0.01; ***p< 0.001.
Results represent the means ± SD performed in triplicate.
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Fig. 4.

Anti-IL-1Rrp2 neutralizing antibody rescues ONJ lesions in mice. (A) A graphic
representation of the timeline used in this study. (B) ELISA for TRAP 5b from the serum
obtained from mice at the end of the experiments. (C) Percent of mice with exposed bone
was assessed (n = 8–10 per group). (D) Clinical illustrations of the osteomucosal tissues at
the tooth-extracted areas (left panels) and µCT scans of the maxillae taken from the occlusal
views (middle panels) and the angled views (right panels). (E) H&E-stained tissues at toothextracted sites. Scale bar = 100 µm. (F, G) The numbers of empty lacunae per mm2 and the
percentage of necrotic bones were quantified. *p<0.05; **p<0.01; ***p< 0.001.
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Proposed model. TGF-β1 binds TGF-β receptor and causes phosphorylation of Smad2/3,
which in turns translocates into the nucleus and activates the target genes such as Col1a1 or
α-Sma. IL-36α binds to IL-36 receptor complex and activates the ERK signaling pathway.
Activated Erk inhibits translocation of TGF-β1-activated Smad complex, thereby
suppressing the Smad-mediated activation of gene expression.
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